CD8A and neoplasm: An analysis of CD4+, CD8+, and OVA-specific CD8+ T cells in the tumor on day 10, but not on day 2 post-treatment start, revealed an increase in numbers in both directly injected and distant tumors in mice treated with VSV-NDV that reached statistical significance for the treated tumor (Figure 2A).